Heart Test Laboratories, Inc.

Company Overview

Business Model: HeartSciences Inc. is a medical technology company focused on enhancing the clinical utility of electrocardiographs (ECGs) through innovative AI-based technology. The company's objective is to expand ECG capabilities to detect a broader range of heart disease conditions using AI-ECG algorithms. HeartSciences Inc. aims to provide these solutions globally, either through its cloud-based application, the MyoVista Insights Cloud Platform, which is designed to be ECG device agnostic, or via its proprietary MyoVistawavECG device. The MyoVistawavECG is a resting 12-lead ECG that incorporates HeartSciences Inc.'s proprietary AI-ECG algorithm for detecting cardiac dysfunction (impaired cardiac relaxation) alongside conventional ECG information. The AI-ECG algorithms are intended to provide diagnostic information traditionally requiring cardiac imaging. The initial revenue model for the MyoVistawavECG device is expected to be "razor-razorblade," involving the capital sale of the device and recurring revenue from proprietary electrodes/consumables. As additional algorithms become commercially available, revenue models are expected to shift towards algorithm usage and/or recurring subscriptions.

Market Position: HeartSciences Inc. identifies a significant diagnostic gap in early heart disease identification, noting the limitations of conventional ECGs in screening broadly for many types of heart disease. The company aims to address this by extending ECG capabilities to detect cardiac dysfunction and other heart disease types. The market opportunity is driven by changing demographics (an aging population with increasing heart disease incidence), a growing global ECG market (estimated at 1.5-3.0 million ECGs performed daily worldwide), an impetus for earlier, low-cost testing to reduce healthcare costs, and the evolving landscape of healthcare providers. If FDA cleared, the primary target markets include frontline healthcare environments in the U.S., such as cardiology, primary care, health systems, retail clinics, and insurers with high Medicare Advantage patient populations. The global ECG market is projected to grow from $10.93 billion in 2023 to $30.87 billion by 2034. The company faces intense competition from established medical device manufacturers like GE Healthcare Technologies, Inc., Koninklijke Philips N.V., Baxter International, Inc., and Nihon Kohden Corporation, as well as new AI-ECG market entrants such as Anumana, Inc., Tempus Labs, Inc., and VIZ.ai.

Recent Strategic Developments:

• Licensing & Collaboration: On September 20, 2023, HeartSciences Inc. entered into multiple definitive license agreements with Icahn School of Medicine at Mount Sinai to commercialize a range of AI-ECG algorithms for various cardiovascular conditions. This also included a memorandum of understanding for ongoing cooperation, data access, and research. In November 2022, the company also entered a multi-year collaboration agreement with Rutgers, The State University of New Jersey, for additional AI-ECG algorithm research and development.
• Regulatory Milestones: In June 2025, HeartSciences Inc. received Breakthrough Device designation from the FDA for the aortic stenosis algorithm licensed from Mount Sinai.
• Intellectual Property: The company was granted a patent from the Indian Patent Office in May 2024 for MyoVista wavelet technology, a patent allowance from the United States Patent and Trademark Office in July 2024 for deep learning-based ventricular dysfunction detection, and a foundational patent from the United States Patent and Trademark Office in June 2025 for estimating echocardiography parameters using an ECG.
• Corporate & Financing: The company's corporate name changed to HeartSciences Inc. on October 17, 2024. In March 2025, HeartSciences Inc. commenced a Series D Preferred Stock Offering, raising approximately $3.1 million in gross proceeds subsequent to April 30, 2025.

Geographic Footprint: HeartSciences Inc.'s initial sales focus will be the U.S. and European markets. The company intends to use a direct sales force in the U.S. following FDA clearance and medical device distributors in markets outside the U.S., such as Europe and Latin America. The company holds 18 international utility patents and 14 international design registrations in jurisdictions including China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia.

Financial Performance

Revenue Analysis

Profitability Metrics (Fiscal 2025):

• Gross Margin: 50.0%
• Operating Margin: -208825.0% (reflecting significant operating losses relative to minimal revenue)
• Net Margin: -219125.0% (reflecting significant net losses relative to minimal revenue)

Investment in Growth:

• R&D Expenditure: $4,386 thousand (109650.0% of revenue, reflecting significant investment in a development-stage company with minimal revenue)
• Capital Expenditures: $30 thousand (comprising $3,157 for property and equipment and $27,031 for intangible assets)
• Strategic Investments: License agreements with Mount Sinai for AI-ECG algorithms and a collaboration agreement with Rutgers, The State University of New Jersey, for AI-ECG algorithm R&D.

Business Segment Analysis

HeartSciences Inc. operates in one operating and reportable segment, focusing on identifying, developing, and commercializing products and AI-ECG solutions in the cardiovascular diagnostic technology field.

Capital Allocation Strategy

Balance Sheet Position:

• Cash and Equivalents: $1,098 thousand (as of April 30, 2025)
• Total Debt: $2,551 thousand (current portion of notes payable as of April 30, 2025)
• Net Cash Position: $(1,453) thousand
• Debt Maturity Profile:
  • FRV Note: $500 thousand principal, matures September 30, 2025. Accrues interest at 12% per annum (18% default rate). Collateralized by substantially all company assets and intellectual property, excluding specific MyoVistawavECG IP.
  • Streeterville Note: Original principal of $2,510 thousand, net proceeds of approximately $1.9 million after Original Issue Discount (OID) and transaction expenses. Bears interest at 8.5% per annum, matures March 2026. Streeterville Capital, LLC may redeem up to $270 thousand per month starting six months post-issuance. Outstanding balance increases by 5% if not reduced by $900 thousand by the 12-month anniversary. Subsequent to April 30, 2025, $870 thousand in principal was exchanged for common stock, and $100 thousand in principal was repaid in cash.

Cash Flow Generation:

• Operating Cash Flow: $(7,413) thousand (Fiscal 2025)
• Free Cash Flow: $(7,443) thousand (Fiscal 2025)

Operational Excellence

Production & Service Model: The MyoVistawavECG device is primarily built from off-the-shelf components, with HeartSciences Inc. relying on third parties for component supply and assembly. The MyoVista Insights Cloud Platform is designed as a cloud-based ECG management system to facilitate efficient review, reporting, and storage of ECGs, capable of hosting both internally developed and third-party AI-ECG algorithms. The platform is designed to be ECG device agnostic.

Supply Chain Architecture: Key Suppliers & Partners:

• Component & Manufacturing: Relies on third-party suppliers for off-the-shelf components and third-party manufacturers for the assembly of the MyoVistawavECG device.
• Technology Partners:
  • Icahn School of Medicine at Mount Sinai: Strategic partner for licensing 13 AI cardiovascular algorithms, two data science methods, and three filed patents, alongside ongoing cooperation for data access, research, and MyoVistawavECG evaluation.
  • Rutgers, The State University of New Jersey: Collaborates on a multi-year agreement for research and development of additional AI-ECG algorithms.
  • The University Court of The University of Glasgow: Holds a non-exclusive, worldwide license for the Glasgow Algorithm, a widely used conventional ECG interpretation algorithm integrated into the MyoVistawavECG.

Facility Network:

• Research & Development: Conducts R&D internally with six full-time staff, supplemented by outside consulting firms for hardware development, multiple software development contractors, and external data science experts for AI-ECG algorithms.
• Headquarters: Leases a 4,634 square foot office suite in Southlake, Texas, with a lease term extending to May 31, 2028.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Plans to establish a direct sales force in the U.S. following FDA clearance.
• Channel Partners: Intends to leverage medical device distributors in international markets, including Europe and Latin America.
• Digital Platforms: The MyoVista Insights Cloud Platform serves as a digital channel for delivering AI-ECG algorithms.

Customer Portfolio: Early Adopters: HeartSciences Inc. has signed two initial customers for the MyoVista Insights cloud application to integrate the platform into clinical workflows and test its features, pending regulatory clearance for AI-ECG algorithms. Target Markets: Key target markets, upon FDA clearance, include cardiology practices, primary care providers (especially concierge medicine), health systems, retail clinics, and insurers with significant Medicare Advantage patient populations.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device industry is characterized by rapid technological advancements, intense competition, and a strong focus on proprietary products. The global ECG market is experiencing growth, with an estimated 1.5 to 3.0 million ECGs performed daily worldwide and over 100 million annually in the United States. The market size is projected to increase from $10.93 billion in 2023 to $30.87 billion by 2034. A significant diagnostic gap exists in the early identification of heart disease, as conventional ECGs have limited sensitivity for structural and ischemic conditions. Cardiovascular disease represents a substantial cost to the U.S. healthcare system, estimated at $240 billion annually, driving a push for earlier, more cost-effective diagnostic solutions.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Traditional ECG Manufacturers: GE Healthcare Technologies, Inc., Koninklijke Philips N.V., Baxter International, Inc., Nihon Kohden Corporation.
• New AI-ECG Market Entrants: Anumana, Inc., Tempus Labs, Inc., VIZ.ai.

Competitive Response Strategy: HeartSciences Inc. aims to maintain its competitive advantage by focusing on developing and commercializing AI-ECG algorithms that expand the clinical utility of ECGs beyond conventional limitations. This includes leveraging its proprietary MyoVistawavECG device and the device-agnostic MyoVista Insights Cloud Platform. The company's strategy involves strategic licensing (e.g., Mount Sinai) and R&D collaborations (e.g., Rutgers) to accelerate product development and market entry. The proposed "razor-razorblade" and subscription-based revenue models are designed to encourage adoption, supported by efforts to secure FDA clearances and CPT codes for reimbursement.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Regulatory Approval: Future operating results are highly dependent on obtaining FDA clearance for the MyoVistawavECG device and the MyoVista Insights Cloud Platform, which has not yet been received. Delays or failure to secure these clearances would prevent the company from marketing and selling its products in the U.S.
• Physician Acceptance: The company's success is contingent on physician awareness and acceptance of its products. Adoption may be slow due to established relationships with competitors, lack of experience with new technologies, or perceived insufficient clinical evidence.
• Reimbursement: Inadequate coverage and reimbursement from third-party payors for AI-ECG algorithms could negatively impact revenue and physician adoption.
• Technology Obsolescence: The medical device industry is characterized by rapid technological change. HeartSciences Inc.'s products could become obsolete if the company fails to keep pace with new developments or acquire new technologies.
• Competition: The company faces intense competition from well-established medical device companies with greater financial and human resources, as well as new entrants in the AI-ECG market.
• Economic Conditions: Business operations are exposed to risks from changes in domestic and global economic conditions, including geopolitical events, inflationary pressures, and interest rate fluctuations, which could adversely affect funding availability and customer spending.
• Public Health Crises: Epidemics, pandemics, or other public health crises could disrupt manufacturing, supply chains, and access to capital, negatively impacting business and operations.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: HeartSciences Inc. relies on third-party manufacturers and suppliers for MyoVistawavECG components and assembly. This dependency creates vulnerability to supply shortages, increased costs, quality issues, and delays, with potential difficulties in identifying and qualifying alternative suppliers.

Data & System Integrity:

• System Failures/Cyber-attacks: The delivery of cardiac monitoring services depends on the uninterrupted availability of third-party cloud-based computational and data management services. Interruptions or security breaches due to cyber-attacks, natural disasters, or technical failures could lead to liability, reputational damage, and operational disruptions.
• Proprietary Data Analytics Engine: The continuous development and operation of the company's deep-learned backend data analytics engine is complex and may encounter unforeseen difficulties, defects, or errors, potentially damaging reputation or diverting resources.

Financial & Regulatory Risks

Market & Financial Risks:

• Funding Needs: The company requires substantial additional funding to support future operations, including clinical trials, commercialization, and R&D. There is no assurance that such funding will be available on acceptable terms, or at all, raising substantial doubt about the company's ability to continue as a going concern.
• Debt Obligations: All company assets are subject to security interests from existing debt. A breach of debt terms could result in accelerated repayment and foreclosure, severely impacting operations.
• Nasdaq Delisting: The company faces a risk of delisting from Nasdaq due to non-compliance with minimum bid price and minimum stockholders’ equity requirements.

Regulatory & Compliance Risks:

• Extensive Regulation: Products and operations are subject to extensive government regulation by the FDA and foreign agencies. Non-compliance could lead to enforcement actions, including fines, injunctions, product recalls, or withdrawal of marketing approvals.
• Product Modifications: Any significant modifications to cleared products may require new 510(k) clearances, potentially delaying market access or necessitating product recalls.
• Clinical Trial Delays/Failures: Clinical studies, often required for regulatory submissions, are lengthy, expensive, and uncertain. Delays or failures, including those involving third-party contractors, could prevent product launches and adversely affect business prospects.
• Post-Marketing Compliance: Ongoing compliance with post-marketing regulations (e.g., QSR, medical device reporting, labeling) is critical. Failure to comply could result in enforcement actions and reputational harm.
• Misuse/Off-label Use: Misuse or promotion of products for unapproved ("off-label") uses could lead to patient harm, product liability suits, and costly regulatory investigations or sanctions.
• Product Recalls: Devices may be subject to recalls due to design flaws, manufacturing defects, or malfunctions, which could harm reputation, lead to liability claims, and negatively impact sales.
• Healthcare Fraud & Abuse Laws: Compliance with federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, HIPAA, False Claims Act, Physician Payments Sunshine Act) is mandatory. Violations could result in substantial penalties and operational restrictions.
• Legislative/Regulatory Reforms: Changes in healthcare legislation or regulations in the U.S. or EU could increase costs, lengthen review times, or restrict the ability to manufacture, market, or distribute devices.
• FDA/Government Agency Disruptions: Funding shortages or global health concerns could hinder regulatory agencies' ability to conduct timely reviews and approvals, impacting the company's business.
• Data Protection Laws: Evolving data protection laws (e.g., HIPAA, CCPA, GDPR) and potential non-compliance pose risks of governmental investigations, significant penalties, and reputational damage.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• AI-based ECG Algorithms (AI-ECG): Primary focus on developing and applying AI-ECG algorithms to expand the clinical usefulness of ECGs for detecting a broader range of heart disease conditions.
• MyoVistawavECG Device: Development of a proprietary 12-lead resting ECG device incorporating an AI-ECG algorithm designed to detect impaired cardiac relaxation (cardiac dysfunction).
• MyoVista Insights Cloud Platform: Development of a cloud-based, ECG device-agnostic platform to host both internally developed and third-party AI-ECG algorithms.

Innovation Pipeline:

• MyoVistawavECG Algorithm: The initial AI-ECG algorithm for the MyoVistawavECG device is designed to detect impaired cardiac relaxation, incorporating age-adjusted measures. The company is currently evaluating alignment with updated LVDD guidelines from July 2025 prior to FDA submission.
• MyoVista Insights Cloud Platform Algorithms: The first AI-ECG algorithm expected for submission as part of the MyoVista Insights Cloud Platform is for the detection of low ejection fraction (LVEF ≤ 40), licensed from Mount Sinai. An FDA submission for this platform and algorithm is aimed for the first half of calendar year 2026.
• Future Algorithms: The company has licensed a pipeline of other AI-ECG algorithms from Mount Sinai and maintains relationships with other clinical institutions for further algorithm development.
• Breakthrough Device Designation: Received Breakthrough Device designation from the FDA in June 2025 for its aortic stenosis ECG algorithm.

Intellectual Property Portfolio:

• Patent Strategy: HeartSciences Inc. protects its technology through a combination of patents and trade secrets.
• Patent Holdings:
  • United States Patent and Trademark Office (USPTO): Holds 8 utility patents, 1 design patent, and 1 patent allowance (exclusively licensed). Patent expiration dates range from March 2031 to August 2040.
  • International Patents: Holds 18 international utility patents and 14 international design registrations, with expiration dates ranging from September 2036 to March 2037, across jurisdictions including China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia.
  • Pending Applications: Has two patent allowances in Europe and Canada, and additional pending patent applications in various jurisdictions.
• Licensing Programs:
  • Inventor Assignment: An agreement from January 2014 transferred ownership of MyoVistawavECG technology and proprietary intellectual property rights from the inventor to the company.
  • Glasgow Licensing Agreement: A December 2015 agreement with The University Court of The University of Glasgow provides a non-exclusive, worldwide license for the Glasgow Algorithm, used for conventional 12-lead ECG analysis.
  • Mount Sinai License Agreements: Multiple agreements from September 2023 grant rights to 13 AI cardiovascular algorithms, two data science methods, and three filed patents.

Technology Partnerships:

• Icahn School of Medicine at Mount Sinai: A key strategic alliance for commercializing AI cardiovascular algorithms and ongoing research collaboration.
• Rutgers, The State University of New Jersey: A multi-year collaboration agreement for the research and development of additional AI-ECG algorithms.
• The University Court of The University of Glasgow: Partner for licensing the Glasgow Algorithm.

Leadership & Governance

Executive Leadership Team

Board Composition: The Board of Directors consists of five members, divided into three classes. A majority of the Board members are independent: Bruce Bent, David R. Wells, and Brian Szymczak.

• Audit Committee: Composed of Bruce Bent (Chairman and "audit committee financial expert"), David R. Wells, and Brian Szymczak, all of whom are independent.
• Compensation Committee: Composed of Bruce Bent, David R. Wells, and Brian Szymczak, all of whom are independent.
• Nominating and Governance Committee: Composed of Bruce Bent, David R. Wells, and Brian Szymczak, all of whom are independent.
• Director Designation: Brian Szymczak was designated as a director pursuant to the MyoVista Technology Agreement, which grants Guangren “Gary” Chen the right to designate a board member.

Human Capital Strategy

Workforce Composition: As of July 23, 2025, HeartSciences Inc. had 15 full-time employees, including its Chief Executive Officer, and 9 independent contractors. The R&D staff comprises six full-time employees focused on hardware, software, and AI-ECG algorithm development.

Talent Management: Acquisition & Retention: The company's employment and consulting agreements include provisions for non-competition, assignment of intellectual property rights, and confidentiality to protect proprietary information and retain key talent.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Food and Drug Administration (FDA): HeartSciences Inc.'s products are subject to extensive regulation under the Federal Food, Drug, and Cosmetic Act (FDCA). The MyoVistawavECG device is classified as a Class II medical device, and the company is preparing for a 510(k) FDA submission in calendar year 2025, while evaluating alignment with updated LVDD guidelines. The MyoVista Insights Cloud Platform and Mount Sinai-licensed AI-ECG algorithms are expected to follow the 510(k) pathway, with an FDA submission aimed for the first half of calendar year 2026. The aortic stenosis algorithm received Breakthrough Device designation from the FDA in June 2025.
• European Economic Area (EEA): To market devices in the EEA, HeartSciences Inc. must comply with the EU Medical Device Regulation (EU MDR). The company's CE Mark under the previous MDD lapsed in February 2022, and it needs to establish compliance under EU MDR.
• Reimbursement: The American Medical Association has issued a temporary Current Procedural Terminology (CPT) Category III code for novel AI assistive algorithmic ECG risk assessment for cardiac dysfunction. HeartSciences Inc. will seek standard ECG reimbursement coding for the conventional functions of the MyoVistawavECG device and private third-party payor reimbursement for its proprietary AI-ECG algorithms.
• Post-Market Compliance: Post-market requirements include establishment registration, device listing, Quality System Regulation (QSR) compliance, labeling and marketing regulations, medical device reporting, correction/removal/recall reporting, and Unique Device Identifiers (UDI).
• Healthcare Fraud and Abuse Laws: The company is subject to federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute, the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the False Claims Act (FCA), and the Physician Payments Sunshine Act.

Trade & Export Controls: HeartSciences Inc. is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.

Tax Strategy & Considerations

Tax Profile: As of April 30, 2025, HeartSciences Inc. had approximately $56 million in cumulative net operating loss (NOL) carryforwards for federal income tax purposes, which begin to expire in 2028. A full valuation allowance has been recorded against deferred tax assets, indicating that the company does not expect to realize the benefits of these deductible differences in the foreseeable future.

Insurance & Risk Transfer

Insurance Coverage: HeartSciences Inc. maintains product liability insurance, though the coverage limits may not be adequate for future claims. The company also holds insurance that may cover certain liabilities related to disruptions, security breaches, and incidents, including cybersecurity risks.